Predicting Pathologic Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer Using Multiparametric MRI

Overview

Journal BMC Med Imaging

Publisher Biomed Central

Specialty Radiology

Date 2021 Oct 24

PMID 34688263

Citations 4

Authors

Nannan Lu

Jie Dong

Xin Fang

Lufang Wang

Wei Jia

Qiong Zhou

Lingyu Wang

Jie Wei

Yueyin Pan

Xinghua Han

Affiliations

Soon will be listed here.

Abstract

Background: This study aims to observe and analyze the effect of diffusion weighted magnetic resonance imaging (MRI) on the patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.

Methods: Fifty patients (mean age, 48.7 years) with stage II-III breast cancer who underwent neoadjuvant chemotherapy and preoperative MRI between 2016 and 2020 were retrospectively evaluated. The associations between preoperative breast MRI findings/clinicopathological features and outcomes of neoadjuvant chemotherapy were assessed.

Results: Clinical stage at baseline (OR: 0.104, 95% confidence interval (CI) 0.021-0.516, P = 0.006) and standard apparent diffusion coefficient (ADC) change (OR: 9.865, 95% CI 1.024-95.021, P = 0.048) were significant predictive factors of the effects of neoadjuvant chemotherapy. The percentage increase of standard ADC value in pathologic complete response (pCR) group was larger than that in non-pCR group at first time point (P < 0.05). A correlation was observed between the change in standard ADC values and tumor diameter at first follow-up (r: 0.438, P < 0.05).

Conclusions: Our findings support that change in standard ADC values and clinical stage at baseline can predict the effects of neoadjuvant chemotherapy for patients with breast cancer in early stage.

Citing Articles

Predictive value of ultrasound doppler parameters in neoadjuvant chemotherapy response of breast cancer: Prospective comparison with magnetic resonance and mammography.

Conz L, Jales R, Doria M, Melloni I, Cres Lyrio C, Menossi C PLoS One. 2024; 19(6):e0302527.

PMID: 38833499 PMC: 11149875. DOI: 10.1371/journal.pone.0302527.

Multiparametric MRI for characterization of the tumour microenvironment.

Hoffmann E, Masthoff M, Kunz W, Seidensticker M, Bobe S, Gerwing M Nat Rev Clin Oncol. 2024; 21(6):428-448.

PMID: 38641651 DOI: 10.1038/s41571-024-00891-1.

Development of a multiparametric model for predicting the response to neoadjuvant chemotherapy in breast cancer.

Qian F, Mao Y, Dong J, Xie F, Fang X, Zhang Q Transl Cancer Res. 2024; 13(2):558-568.

PMID: 38482410 PMC: 10928635. DOI: 10.21037/tcr-23-770.

Evaluation of pretreatment ADC values as predictors of treatment response to neoadjuvant chemotherapy in patients with breast cancer - a multicenter study.

Surov A, Pech M, Meyer H, Bitencourt A, Fujimoto H, Baxter G Cancer Imaging. 2022; 22(1):68.

PMID: 36494872 PMC: 9733082. DOI: 10.1186/s40644-022-00501-2.

References

Park S, Moon W, Cho N, Song I, Chang J, Park I . Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology. 2010; 257(1):56-63. DOI: 10.1148/radiol.10092021. View

Zhang X, Sun Y, Tang L, Xue W, Zhang X . Correlation of diffusion-weighted imaging data with apoptotic and proliferation indexes in CT26 colorectal tumor homografts in balb/c mouse. J Magn Reson Imaging. 2011; 33(5):1171-6. DOI: 10.1002/jmri.22558. View

Bufi E, Belli P, Costantini M, Cipriani A, Di Matteo M, Bonatesta A . Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer. Clin Breast Cancer. 2015; 15(5):370-80. DOI: 10.1016/j.clbc.2015.02.002. View

Kang J, Youk J, Kim J, Gweon H, Eun N, Ko K . Identification of Preoperative Magnetic Resonance Imaging Features Associated with Positive Resection Margins in Breast Cancer: A Retrospective Study. Korean J Radiol. 2018; 19(5):897-904. PMC: 6082768. DOI: 10.3348/kjr.2018.19.5.897. View

Galban C, Hoff B, Chenevert T, Ross B . Diffusion MRI in early cancer therapeutic response assessment. NMR Biomed. 2016; 30(3). PMC: 4947029. DOI: 10.1002/nbm.3458. View

Kuhl C, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J . Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?. Radiology. 1999; 211(1):101-10. DOI: 10.1148/radiology.211.1.r99ap38101. View

Romero A, Garcia-Saenz J, Fuentes-Ferrer M, Lopez Garcia-Asenjo J, Furio V, Roman J . Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients. Ann Oncol. 2012; 24(3):655-61. DOI: 10.1093/annonc/mds493. View

Galban C, Ma B, Malyarenko D, Pickles M, Heist K, Henry N . Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy. PLoS One. 2015; 10(3):e0122151. PMC: 4376686. DOI: 10.1371/journal.pone.0122151. View

Gralow J, Burstein H, Wood W, Hortobagyi G, Gianni L, von Minckwitz G . Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008; 26(5):814-9. DOI: 10.1200/JCO.2007.15.3510. View

10.

Kwong M, Chung G, Horvath L, Ward B, Hsu A, Carter D . Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer. Cancer J. 2006; 12(3):212-21. DOI: 10.1097/00130404-200605000-00010. View

11.

Partridge S, Nissan N, Rahbar H, Kitsch A, Sigmund E . Diffusion-weighted breast MRI: Clinical applications and emerging techniques. J Magn Reson Imaging. 2016; 45(2):337-355. PMC: 5222835. DOI: 10.1002/jmri.25479. View

12.

Yuan C, Jin F, Guo X, Zhao S, Li W, Guo H . Correlation Analysis of Breast Cancer DWI Combined with DCE-MRI Imaging Features with Molecular Subtypes and Prognostic Factors. J Med Syst. 2019; 43(4):83. DOI: 10.1007/s10916-019-1197-5. View

13.

Yuan J, Wong O, Lo G, Chan H, Wong T, Cheung P . Statistical assessment of bi-exponential diffusion weighted imaging signal characteristics induced by intravoxel incoherent motion in malignant breast tumors. Quant Imaging Med Surg. 2016; 6(4):418-429. PMC: 5009105. DOI: 10.21037/qims.2016.08.05. View

14.

Uematsu T, Kasami M, Yuen S . Neoadjuvant chemotherapy for breast cancer: correlation between the baseline MR imaging findings and responses to therapy. Eur Radiol. 2010; 20(10):2315-22. DOI: 10.1007/s00330-010-1813-8. View

15.

Wang Q, Guo Y, Zhang J, Wang Z, Huang M, Zhang Y . Contribution of IVIM to Conventional Dynamic Contrast-Enhanced and Diffusion-Weighted MRI in Differentiating Benign from Malignant Breast Masses. Breast Care (Basel). 2016; 11(4):254-258. PMC: 5040879. DOI: 10.1159/000447765. View

16.

Liu S, Ren R, Chen Z, Wang Y, Fan T, Li C . Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy. J Magn Reson Imaging. 2015; 42(3):779-87. DOI: 10.1002/jmri.24843. View

17.

Wu M, Lu L, Zhang Q, Guo Q, Zhao F, Li T . Relating Doses of Contrast Agent Administered to TIC and Semi-Quantitative Parameters on DCE-MRI: Based on a Murine Breast Tumor Model. PLoS One. 2016; 11(2):e0149279. PMC: 4767184. DOI: 10.1371/journal.pone.0149279. View

18.

Fliedner F, Engel T, El-Ali H, Hansen A, Kjaer A . Diffusion weighted magnetic resonance imaging (DW-MRI) as a non-invasive, tissue cellularity marker to monitor cancer treatment response. BMC Cancer. 2020; 20(1):134. PMC: 7031987. DOI: 10.1186/s12885-020-6617-x. View

19.

Afaq A, Andreou A, Koh D . Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how?. Cancer Imaging. 2010; 10 Spec no A:S179-88. PMC: 2967137. DOI: 10.1102/1470-7330.2010.9032. View

20.

Li X, Cheng L, Liu M, Zhang Y, Wang J, Zhang A . DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Med Oncol. 2011; 29(2):425-31. DOI: 10.1007/s12032-011-9842-y. View